Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

By Shayne Michelle   Crawford Jeffrey   Dale David   Culakova Eva   Lyman Gary  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 255-262

Springer Publishing Company

Access to resources Recommend Favorite

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

By Edlund Per   Ahlgren Johan   Bjerre Karsten   Andersson Michael   Bergh Jonas   Mouridsen Henning   Holmberg Stig B.   Bengtsson Nils-Olof   Jakobsen Erik   Møøller Susanne   Lindman Henrik   Blomqvist Carl  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 329-337

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients

By Jakesz R.   Samonigg H.   Gnant M.   Kubista E.   Steindorfer P.   Hausmaninger H.   Sevelda P.   Tschurtschenthaler B.   Fridrik M.   Stierer M.   Kolb R.   Steger G.   the Austrian Breast Cancer Study Group  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 66-70

Elsevier

Access to resources Recommend Favorite

Current status of dose-dense chemotherapy for breast cancer

By Seidman Andrew  

Cancer Chemotherapy and Pharmacology, Vol. 56, Iss. 1, 2005-11 ,pp. : 78-83

Springer Publishing Company

Access to resources Recommend Favorite